ARS Pharmaceuticals, Inc. Proceeds from Sale of Short-term Investments
ARS Pharmaceuticals, Inc. (SPRY) reported Proceeds from Sale of Short-term Investments of $42.50 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfShortTermInvestments · last filed 2026-05-15
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for the quarter ending 2026-03-31 was $42.50M, a 33.07% decline year-over-year.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for the quarter ending 2025-12-31 was $75.00M, a 11.94% increase year-over-year.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for the quarter ending 2025-09-30 was $88.50M, a 45.08% increase year-over-year.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for the quarter ending 2025-06-30 was $80.00M, a 6.67% increase year-over-year.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for fiscal 2025 was $307.00M, a 18.99% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for fiscal 2024 was $258.00M, a 39.46% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for fiscal 2023 was $185.00M.
- ARS Pharmaceuticals, Inc. proceeds from sale of short-term investments for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale of Short-term Investments 3 month | Proceeds from Sale of Short-term Investments 6 month | Proceeds from Sale of Short-term Investments 9 month | Proceeds from Sale of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-03-31 | $42.50M 10-Q · filed 2026-05-15 | $117.50M derived: sum of 2 quarters · filed 2026-05-15 | $206.00M derived: sum of 3 quarters · filed 2026-05-15 | $286.00M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $75.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $163.50M derived: sum of 2 quarters · filed 2026-03-09 | $243.50M derived: sum of 3 quarters · filed 2026-03-09 | $307.00M 10-K · filed 2026-03-09 |
| 2025-09-30 | $88.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $168.50M derived: sum of 2 quarters · filed 2025-11-10 | $232.00M 10-Q · filed 2025-11-10 | $299.00M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-06-30 | $80.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $143.50M 10-Q · filed 2025-08-13 | $210.50M derived: sum of 3 quarters · filed 2026-05-15 | $271.50M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-03-31 | $63.50M 10-Q · filed 2026-05-15 | $130.50M derived: sum of 2 quarters · filed 2026-05-15 | $191.50M derived: sum of 3 quarters · filed 2026-05-15 | $266.50M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $67.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $128.00M derived: sum of 2 quarters · filed 2026-03-09 | $203.00M derived: sum of 3 quarters · filed 2026-03-09 | $258.00M 10-K · filed 2026-03-09 |
| 2024-09-30 | $61.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $136.00M derived: sum of 2 quarters · filed 2025-11-10 | $191.00M 10-Q · filed 2025-11-10 | $251.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $75.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $130.00M 10-Q · filed 2025-08-13 | $190.00M derived: sum of 3 quarters · filed 2025-08-13 | $250.00M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $55.00M 10-Q · filed 2025-05-14 | $115.00M derived: sum of 2 quarters · filed 2025-05-14 | $175.00M derived: sum of 3 quarters · filed 2025-05-14 | $220.00M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $60.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $120.00M derived: sum of 2 quarters · filed 2025-03-20 | $165.00M derived: sum of 3 quarters · filed 2025-03-20 | $185.00M 10-K · filed 2025-03-20 |
| 2023-09-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $105.00M derived: sum of 2 quarters · filed 2024-11-13 | $125.00M 10-Q · filed 2024-11-13 | $125.00M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $65.00M 10-Q · filed 2024-08-06 | $65.00M derived: sum of 3 quarters · filed 2024-08-06 | $65.00M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $20.00M 10-Q · filed 2024-05-09 | $20.00M derived: sum of 2 quarters · filed 2024-05-09 | $20.00M derived: sum of 3 quarters · filed 2024-05-09 | $20.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |